Clinical profile of the novel sulphonylurea glimepiride

Diabetes Research and Clinical Practice

Volumn 31, Issue SUPPL., 1996, Pages

  Rosskamp R ^a   Wernicke Panten, K ^a   Draeger, E ^a  

^a SANOFI   (France)

Author keywords

Glimepiride; Sulphonylurea; Type II diabetes

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GUANIDINE DERIVATIVE; ORAL ANTIDIABETIC AGENT; PLACEBO; POTASSIUM CHANNEL; SULFONYLUREA DERIVATIVE;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0343807392     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-8227(96)01228-4     Document Type: Conference Paper

References (13)

1. United Kingdom Prospective Diabetes Study Group (1995) United Kingdom prospective diabetes study (UKPDS) 13; relative efficacy of randomly allocated diet, sulphonylurea, insulin or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. Br. Med. J. 310, 83-88.
2. Geisen, K. (1988) Special pharmacology of the new sulphonylurea glimepiride. Arzneimittel Forschung Drug Res. 38, 1120-1130.
3. Gudat, L. and Heinemann, L. (1996) Einfenß von Kérperlicher belestung auf die glykämie von stoffwediselgesunden probanden nach einnalune von glimepirid. Arzneim.-Forsch./Drug Res., in press.
4. ®) after oral administration. Drug Metab. Drug Interactions 11(4), 331-339.
5. ®) tablets in healthy volunteers. Drug Metab. Drug Interactions 11(4), 341-357.
6. Wernicke-Panten, K., Haupt, E., Pfeiffer, C., Mayer, A. and Draeger, K.E. (1994) Early onset of pharmacodynamic effects of glimepiride in type II diabetic patients. Diabetologia 37(Suppl. 1), abs. 628.
7. Draeger, K.E., Lomp, H.-J. and Roßkamp, R. (1994) Multicentre clinical trial to study the effect of glimepiride during long-term treatment of type II diabetic patients. Diabetologia 37(Suppl. 1), abs 185.
8. Ducimetière, P., Eschwège, E., Papoz, L., Richard, J.L., Claude, J.R. and Rosselin, G.E. (1980) Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 19, 205-210.
9. Fontbonne, A.M. and Eschwège, E.M. (1991) Insulin and cardiovascular disease - Paris prospective study. Diabetes Care 14, 461-469.
10. ®): a double-blind comparison with glibenclamide. Diabetologia, in press.
11. University Group Diabetes Program (1970) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes mellitus. II. Mortality results. Diabetes 19(Suppl. 2), 785-830.
12. Gilbert, J.P., Saracci, R., Meier, P., Zelen, M., Rümke, C. and White, C. (1975) Report of the committee for the assessment of biometric aspects of controlled trials of hypoglycemic agents. J. Am. Med. Assoc. 231, 583-608.
13. Smits, P. and Thien, T. (1995) Cardiovascular effects of sulphonylurea derivatives. Diabetologia 38, 116-121.